• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cook, AcuityBio ink deal for lung cancer drug technology

September 6, 2018 By Nancy Crotti

Cook Biotech will collaborate with drug-delivery maker AcuityBio on Acuity’s lead lung cancer product, the companies said today.

Acuity’s ABC103 will use Cook Biotech’s proprietary extracellular matrix (ECM) technology. ABC103 is a platform technology designed for localized, sustained drug delivery to prevent post-surgical lung cancer recurrence. It combines approved/ cleared surgical staple-line buttress, drug-eluting polymers and a chemotherapeutic drug, paclitaxel.

The FDA has granted ABC103 orphan drug designation for this indication. Phase I clinical testing of is scheduled to begin in late 2019. Acuity is developing other applications for the ABC drug-delivery platform.

“We believe that the solidification of our relationship with Cook Biotech will allow us to build on our two companies’ strengths, such as AcuityBio’s drug-delivery expertise and Cook Biotech’s unique medical device technology platform, know-how, and market experience,” said John Schwartz, president & CEO of Newton, Mass.-based Acuity Bio, in a prepared statement. “Working together will speed development of our combined AcuityBio-Cook Biotech lead product for lung cancer, ABC103, ultimately providing a solution to a critical unmet medical need and the betterment of patient outcomes.”

“For more than 20 years, our ECM technology has been used to improve the lives of patients worldwide,” addedCook Biotech President Umesh Patel. “We are excited to partner with AcuityBio to help bring a medical solution that can potentially save lives.”

The terms of the agreements remain confidential. Acuity Bio is the latest addition to the list of partners and distributors for Cook Biotech. An affiliate of Cook Medical, the biotech company has agreements with AxoGen Inc., Aziyo Biologics, Cook Medical, Cormatrix, Katena Products, Keystone Dental, Progressive Medical, and Smith & Nephew to develop new products and provide technical support.

In July, Cook Medical announced the launch and first use of its Advance CS coronary sinus infusion catheter and Compass CT disposable pressure transducer designed for treating heart failure patients.

 

 

 

 

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Oncology Tagged With: acuitybio, cookbiotech, FDA

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS